Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corporation (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. The CAMP news feed highlights how the company advances its antisense oligonucleotide (ASO) pipeline, progresses clinical and preclinical programs, and enters strategic collaborations.
Readers can follow CAMP4’s updates on its SYNGAP1-related disorders program, including announcements about GLP toxicology studies for CMP-SYNGAP-01, translational data in humanized mouse models and non-human primates, and plans for Phase 1/2 clinical trial applications. News items also cover the company’s Urea Cycle Disorders program and the CMP-CPS-001 (CMP-001) Phase 1 trial, where CAMP4 has reported safety and pharmacokinetics data from single and multiple ascending dose cohorts in healthy volunteers.
CAMP4’s news flow includes financial and corporate updates such as private placements, underwritten offerings of common stock, and use of proceeds to support development of its product candidates. The company also reports on strategic agreements, including a research, collaboration and license agreement with GSK to discover and develop ASO drug candidates for neurodegenerative and kidney disease indications using CAMP4’s RAP Platform.
In addition, CAMP4 issues press releases on scientific presentations at major meetings, corporate highlights, and inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this news page to review CAMP4’s reported milestones, research progress, and financing activities related to its regulatory RNA-targeting therapeutic strategy.
CAMP4 Therapeutics (Nasdaq: CAMP) announced on December 11, 2025 that its Board approved inducement grants under Nasdaq Listing Rule 5635(c)(4).
The Board granted non-qualified stock options to purchase an aggregate of 92,000 shares to four newly hired employees. Each option has a ten-year term and an exercise price of $6.01, equal to CAMP4’s closing share price on the grant date.
The options vest over four years with 25% vesting at the one-year anniversary and the remainder vesting in 36 equal monthly installments, subject to continued service and the terms of an Inducement Option Award Agreement.
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement stock option grant on November 12, 2025 to a newly hired employee under Nasdaq Listing Rule 5635(c)(4).
The Board granted a non‑qualified option to purchase 80,000 shares with a 10‑year term and an exercise price of $4.39, equal to the closing price on the grant date. The option vests over four years: 25% after one year, then the remainder in 36 monthly installments, subject to continued service, and is governed by an Inducement Option Award Agreement.
CAMP (Nasdaq: CAMP) reported Q3 2025 results and corporate updates on Nov 6, 2025. Key items include a private placement initial closing of $50M (up to $100M total) that management says extends runway into 2027, and cash and marketable securities of $75.3M as of Sept 30, 2025 (up from $39.1M on June 30, 2025).
Clinical progress: initiated GLP toxicology studies for CMP-002 to support a planned Phase 1/2 filing with potential trial start as early as H2 2026; completed MAD analysis for CMP-001 showing favorable safety and PK and received a Netherlands CTA to start a Phase 1b in OTC heterozygotes. Q3 operating items: R&D $9.4M, G&A $4.6M, net loss $15.1M.
CAMP4 Therapeutics (Nasdaq: CAMP) has initiated GLP toxicology studies for CMP-SYNGAP-01, their lead product candidate targeting SYNGAP1-related disorders. The company aims to submit a clinical trial application that could lead to a Phase 1/2 clinical trial beginning in H2 2026.
Preclinical studies have shown promising results, with CMP-SYNGAP-01 successfully restoring SYNGAP1 protein levels in mouse models and increasing protein levels in relevant brain regions of non-human primates. SYNGAP1-related disorders, affecting 0.5% to 1.0% of intellectual disability cases, currently lack FDA-approved disease-modifying treatments.
CAMP4 Therapeutics (NASDAQ: CAMP) has secured an oversubscribed private placement of up to $100 million to advance its SYNGAP1 program. The financing includes $50 million in upfront proceeds and potential for an additional $50 million tied to achieving specific milestones, including regulatory clearance for a Phase 1/2 clinical trial.
The initial financing comprises 26,681,053 shares of common stock at $1.53 per share, with additional shares for directors and employees at $1.65, and pre-funded warrants. The placement is led by Coastlands Capital, with participation from investors including Janus Henderson, Balyasny Asset Management, and Vivo Capital.
Alongside this financing, Doug Williams, Ph.D., has been appointed as Board Chair, and Daniel Tardiff, Ph.D., will become Chief Scientific Officer effective October 1, 2025. The company plans to initiate its Phase 1/2 clinical trial for SYNGAP1-related disorders as early as 2H 2026.
CAMP4 Therapeutics (NASDAQ:CAMP) reported Q2 2025 financial results and corporate updates, highlighting progress in its RNA-targeting therapeutics pipeline. The company presented positive translational data for its SYNGAP1-related disorders program at the ASGCT Annual Meeting, demonstrating efficacy in mouse models and increased protein levels in non-human primates.
Key developments include plans to initiate GLP toxicology studies for CMP-SYNGAP-01 in Q3 2025, with potential Phase 1/2 trial initiation in H2 2026. The company completed dosing in the third MAD cohort for CMP-CPS-001, with comprehensive data expected in Q4 2025. Financial position shows $39.1 million in cash and equivalents, with Q2 R&D expenses of $10.3 million and a net loss of $12.6 million.
CAMP4 Therapeutics (Nasdaq: CAMP) has announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy in New Orleans, May 13-17, 2025.
The presentations will showcase:
- Preclinical data on regulatory RNA-targeting to increase protein levels for gene expression
- Interim safety data from Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers
- Research on potential treatments for Urea Cycle Disorders and SYNGAP1-Related Disorders
Three key presentations by the company include:
- Two presentations by Dr. Dan Tardiff on targeting regulatory RNAs for treating Urea Cycle Disorders and SYNGAP1-Related Disorders
- One presentation by Dr. Yuri Maricich on the first-in-human clinical trial results of CMP-CPS-001
All presentations will take place on May 16, 2025, during the Oligonucleotide Therapeutics II session and will be available on the company's investor website.
CAMP4 Therapeutics (NASDAQ: CAMP) reported its full year 2024 financial results and provided updates on its clinical programs. The company's Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders (UCDs) is progressing, with two of four multiple ascending dose cohorts completed. Safety data is expected in Q4 2025.
Key financial highlights include:
- R&D expenses: $38.8 million (down from $40.6 million in 2023)
- G&A expenses: $14.9 million (up from $11.6 million in 2023)
- Net loss: $51.8 million (compared to $49.3 million in 2023)
- Cash position: $64.0 million (sufficient until Q2 2026)
The company nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders and plans to initiate GLP toxicology studies in 2025. CAMP4 also expects to begin a Phase 1b trial in female OTC heterozygotes in Q2 2025.